ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2026
The impact of obstructive sleep apnea on idiopathic pulmonary fibrosis clinical outcomes.
Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectiveCurrent literature suggests that obstructive sleep apnea (OSA) occurs in 59–88% of patients with idiopathic pulmonary fibrosis (IPF), with studies proposing that intermittent hypoxemia and elevated levels of inflammatory cytokines from OSA may exacerbate fibrosis progression and worsen hypoxemia, resulting in higher morbidity and mortality. This study seeks to further characterize the association between OSA and IPF progression and its impact on hospitalization and mortality.
methodsDe-identified administrative claims data from the OptumLabs Data Warehouse (OLDW) were obtained from January 2016 through June 2024. Patients with OSA and IPF were identified using ICD-10 codes. A final 1:1 propensity score-matched cohort was constructed to balance confounding factors. Primary outcomes were respiratory-related hospitalizations and all-cause mortality between the groups. Secondary analyses explored factors that were associated with increased hospitalization or mortality.
resultsOf 21,469 patients with IPF, 31% had concomitant OSA. Overall, 26% of the patients in the IPF only group and 33% in the IPF + OSA group were treated with an antifibrotic. In addition, 36% of the patients in the IPF group and 46% in the IPF + OSA group received supplemental oxygen. Of the patients with OSA, 34% were treated with CPAP. After propensity score matching, 46% mortality was noted in the IPF group compared to 38% in the IPF + OSA group (p < 0.001) with higher mortality and hospitalizations in patients not on CPAP. There was no difference in respiratory-related hospitalizations between the two groups.
conclusionThis study highlights a substantial overlap of OSA in IPF patients and suggests potential survival benefits for those with comorbid OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.